DGAP-Adhoc

Elanix Biotechnologies AG: capital increase successfully placed, gross issuing proceeds amount to some EUR 4.76 million

DGAP-Ad-hoc: Elanix Biotechnologies AG / Key word(s): Capital Increase Elanix Biotechnologies AG: capital increase successfully placed, gross issuing proceeds amount to some EUR 4.76 million 24-Feb-2017 / 17:41 CET/CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Elanix Biotechnologies AG: capital increase successfully placed, gross issuing proceeds amount to approx. EUR 4.76 million

THE INFORMATION CONTAINED IN THIS DISCLOSURE IS NOT INTENDED FOR
PUBLICATION OR DISSEMINATION IN THE UNITED STATES OF AMERICA, AUSTRALIA,
CANADA OR JAPAN

Potsdam, 24 February 2017 - On 30 January 2017 Elanix Biotechnologies AG
(Frankfurt Stock Exchange: ELN, "Elanix", "Company") has resolved to
implement a capital increase against cash contribution from authorized
capital by up to 1,133,200 New Shares, offering an indirect subscription
right to shareholders.

All 1,133,200 New Shares have been fully placed within the scope of the
preemptive rights offering and a private placement. The capital increase
was oversubscribed due to the high level of interest, hence subscriptions
had to be re-allotted equally.

The subscription price per New Share amounted to EUR 4.20. In total the
gross placement volume amounts to approx. EUR 4.76 million which will be
used to cover the operational expenses of the Company and the further
development of marketing the Company's main product GynRepair(R), which is
already available in Switzerland, within the European Union as of Q2 2017.

Tomas Svoboda, CEO

Contact / Investor Relations

Maria Widowski

E-mail: [e-mail]
Telephone number: [phone]

About Elanix

Elanix Biotechnologies (Frankfurt: ELN) develops and commercializes tissue
regeneration products for acute wound care, dermatological and
gynecological applications, and provides services in cell technologies. The